// App-Quantinova.ai

666 : A novel, highly selective PI3Kδ inhibitor for the treatment of solid malignancies that express high levels of target protein as assessed by immunohistochemistry

Researchers

Presenter

  • Amy R. MacQueen

Principal Investigators

  • Giuditta Viticchie

  • Karolina Niewola

  • Francesca Finotello

  • Ian Powley

  • Pritom Shah

  • Lars van der Veen

  • Michael Lahn

  • Zoe Johnson

Medical Centers

  • Cancer Research UK, Southampton, United Kingdom

  • Leicester Cancer Research Centre, United Kingdom

  • iOnctura SA, Switzerland

  • Innsbruck Medical University, Innsbruck, Austria

Locations

  • United Kingdom

  • Switzerland

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Solid malignancies

  • B cell lymphomas

  • Uveal melanoma

  • Lymphomas

  • Melanoma

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform

  • Cluster of differentiation 8A

  • Regulatory T cells

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved